Sigma Planning Corp’s PTC Therapeutics PTCT Stock Holding History

Sigma Planning Corp’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,010	Closed	-$760K	–	1381
2025 Q4	$760K	Buy	+10,010	New	+$727K	0.02%	634

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Sigma Planning Corp's PTCT Position: Q1 2026 in Review

Sigma Planning Corp sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 10,010 shares — an estimated $760K sold.

Sigma Planning Corp first reported a position in PTCT in Q4 2025 and held it in 1 quarter. The position peaked at $760K in Q4 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Sigma Planning Corp reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
Sigma Planning Corp sold 10,010 PTC Therapeutics shares in Q1 2026, an estimated $760K.
Sigma Planning Corp first reported a position in PTC Therapeutics in Q4 2025 and held it in 1 quarter.
Sigma Planning Corp's PTC Therapeutics position peaked at $760K in Q4 2025.
352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.